Reveromycin A Inhibits Antigen Receptor-mediated Antigen Presentation by B Lymphoma Cells via Its Effect on Intracellular Trafficking of the Antigen.

DOI PubMed 被引用文献3件 参考文献41件
  • TANAKA YURIKO
    Department of Immunology, Toho University School of Medicine
  • ISHIKAWA FUMIO
    Department of Immunology, Toho University School of Medicine
  • OSADA HIROYUKI
    Antibiotic Laboratory, The Institute of Physical and Chemical Research (RIKEN)
  • IMAJOH-OHMI SHINOBU
    Department of Basic Medical Science, The Institute of Medical Science, The University of Tokyo
  • UCHIDA TETSUYA
    Department of Safety Research on Biologics, National Institute of Infectious Disease
  • KAKIUCHI TERUTAKA
    Department of Immunology, Toho University School of Medicine

この論文をさがす

抄録

Reveromycin A (Rev.A) is an inhibitor of epidermal growth factor-dependent cell growth that is produced from the culture broth of an actinomycete strain. Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA323-339/I-Ad. Rev.A-treatment inhibited the presentation of Ag internalized via sIgM, but not of Ag via fluid-phase pinocytosis. Rev.A-treatment decreased protein synthesis, but a similar decrease in protein synthesis by cycloheximide induced much less inhibition of sIgM-mediated Ag presentation. Rev.A-treatment decreased the rate of re-expression of sIgM in A20-HL cells, the amount of Ag internalized via sIgM during 3 hours of incubation, and the generation of antigenic peptides from TNP-OVA internalized via sIgM. Rev.A-treatment was suggested to affect intracellular trafficking from early endosomes into late endocytic compartments of Ag internalized via sIgM. Rev.A might provide a useful tool for studying intracellular transport of Ag, especially Ag internalized via sIgM.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (41)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ